Compare UTI & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTI | NVCR |
|---|---|---|
| Founded | 1965 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2003 | 2015 |
| Metric | UTI | NVCR |
|---|---|---|
| Price | $34.40 | $12.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $37.50 | $28.08 |
| AVG Volume (30 Days) | 910.4K | ★ 2.6M |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.67 | 21.79 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $835,616,000.00 | $655,353,000.00 |
| Revenue This Year | $10.15 | $7.72 |
| Revenue Next Year | $8.23 | $6.74 |
| P/E Ratio | $149.26 | ★ N/A |
| Revenue Growth | ★ 14.05 | 8.28 |
| 52 Week Low | $21.29 | $9.82 |
| 52 Week High | $38.02 | $20.87 |
| Indicator | UTI | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 59.08 | 49.71 |
| Support Level | $30.22 | $10.86 |
| Resistance Level | $35.47 | $14.02 |
| Average True Range (ATR) | 1.62 | 0.97 |
| MACD | -0.16 | 0.01 |
| Stochastic Oscillator | 56.13 | 38.52 |
Universal Technical Institute Inc is an educational institution. It provides undergraduate degree, as well as certificate programs for technicians in the automotive, diesel, collision repair, motorcycle and marine fields. The company's reportable segment which includes Universal Technical Institute (UTI) and Concorde Career Colleges, Corporate. Majority of the revenue is generated from UTI segment which provides different kinds of degree and non-degree transportation and skilled trades technical training programs under brands such as Universal Technical Institute, Motorcycle Mechanics Institute, Marine Mechanics Institute and others. It also provides dealer technician training or instructor staffing services to manufacturers.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.